Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

[1]  H. Schöder,et al.  Assessment of salivary gland function after 177Lu-PSMA radioligand therapy: Current concepts in imaging and management , 2022, Translational oncology.

[2]  C. Stokke,et al.  EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  K. Pienta,et al.  177Lu‐PSMA radioligand therapy effectiveness in metastatic castration‐resistant prostate cancer: An updated systematic review and meta‐analysis , 2022, The Prostate.

[4]  J. Czernin,et al.  Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with 177Lu-PSMA Therapy: A Multicenter Retrospective Analysis , 2022, The Journal of Nuclear Medicine.

[5]  K. Rahbar,et al.  Dosimetry of 177Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: results from the VISION trial sub-study. , 2022, Journal of Clinical Oncology.

[6]  I. Burger,et al.  Predicting the outcome of mCPRC patients after Lu-177 PSMA therapy using semi-quantitative and visual criteria in baseline PSMA PET: An international multicenter retrospective study. , 2022, Journal of Clinical Oncology.

[7]  R. Messmann,et al.  Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial , 2022, The Journal of Nuclear Medicine.

[8]  G. Gandaglia,et al.  Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review , 2022, Therapeutic advances in medical oncology.

[9]  M. Boerries,et al.  Early PSA Change after [177Lu]PSMA-617 Radioligand Therapy as a Predicator of Biochemical Response and Overall Survival , 2021, Cancers.

[10]  Xiaoyuan Chen,et al.  Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry , 2021, The Journal of Nuclear Medicine.

[11]  S. Singh,et al.  177Lu-PSMA-617 versus docetaxel in chemotherapy-naïve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  J. Czernin,et al.  PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy , 2021, The Journal of Nuclear Medicine.

[13]  W. Oyen,et al.  Nuclear medicine theranostics comes of age. , 2021, The Lancet. Oncology.

[14]  Steffie M. B. Peters,et al.  [68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  M. Deevband,et al.  Patient-Specific Dosimetry in Radioligand Therapy (RLT) for Metastatic Prostate Cancer Using 177Lu-DKFZ-PSMA-617 , 2021, Nuclear Medicine and Molecular Imaging.

[16]  W. Weber,et al.  Pretherapeutic Comparative Dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer , 2021, The Journal of Nuclear Medicine.

[17]  M. Bartholomä,et al.  castration‐resistant prostate cancer: Initial 254‐patient results from a prospective registry (REALITY Study) Fadi Khreish1 · Zaidoon Ghazal1 · Robert J. Marlowe3 · Florian Rosar1 · Amir Sabet1 · Stephan Maus1 · Johannes Linxweiler2 · Mark Bartholomä1 · Samer Ezziddin1 , 2021 .

[18]  S. Basu,et al.  Combined 177Lu‐PSMA‐617 PRLT and abiraterone acetate versus 177Lu‐PSMA‐617 PRLT monotherapy in metastatic castration‐resistant prostate cancer: An observational study comparing the response and durability , 2021, The Prostate.

[19]  B. Krause,et al.  Streamlined Schemes for Dosimetry of 177Lu-Labeled PSMA Targeting Radioligands in Therapy of Prostate Cancer , 2021, Cancers.

[20]  T. Chaiwatanarat,et al.  Patient dosimetry of 177Lu-PSMA I&T in metastatic prostate cancer treatment: the experience in Thailand , 2021, Annals of Nuclear Medicine.

[21]  Pawan K Gupta,et al.  Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312) , 2021, The Journal of Nuclear Medicine.

[22]  B. Hadaschik,et al.  Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. , 2021, The Lancet. Oncology.

[23]  Steffie M. B. Peters,et al.  Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  M. Mitterhauser,et al.  Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [177Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer , 2021, European urology open science.

[25]  K. Rahbar,et al.  Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. , 2021, The New England journal of medicine.

[26]  M. Mix,et al.  Kidney Doses in 177Lu-Based Radioligand Therapy in Prostate Cancer: Is Dose Estimation Based on Reduced Dosimetry Measurements Feasible? , 2021, The Journal of Nuclear Medicine.

[27]  M. Bartholomä,et al.  Renal Safety of [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function , 2021, Cancers.

[28]  T. Derlin,et al.  PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under 177Lu-PSMA-617 Radioligand Therapy , 2021, Cancers.

[29]  Pawan K Gupta,et al.  Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with 177Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort , 2021, The Journal of Nuclear Medicine.

[30]  A. Seth,et al.  Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients , 2021, PloS one.

[31]  A. Schaefer-Schuler,et al.  Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy , 2021, EJNMMI Physics.

[32]  M. Mitterhauser,et al.  Response and Toxicity to the Second Course of 3 Cycles of 177Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer , 2021, Cancers.

[33]  R. McBean,et al.  Lu177‐PSMA therapy for men with advanced prostate cancer: 18 months survival analysis in a single Australian tertiary institution , 2021, Journal of medical imaging and radiation oncology.

[34]  K. Pienta,et al.  A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer. , 2021, European urology.

[35]  C. Jilg,et al.  Assessing Response to 177Lu-PSMA Radioligand Therapy Using Modified PSMA PET Progression Criteria , 2021, The Journal of Nuclear Medicine.

[36]  W. Brenner,et al.  In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2nd Cycle Is Better Predictor of Overall Survival of Prostate Cancer Patients Treated With 177Lu-PSMA , 2021, Frontiers in Oncology.

[37]  G. Böning,et al.  Correlation of an Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after 177Lu-PSMA-617 Radioligand Therapy , 2021, Diagnostics.

[38]  N. Lenzo,et al.  Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients , 2021, Diagnostics.

[39]  E. Karabulut,et al.  Predictive factors of tumor sink effect: Insights from 177Lu-Prostate-specific membrane antigen therapy , 2021, Annals of Nuclear Medicine.

[40]  R. Bekiş,et al.  Factors affecting overall survival and progression-free survival in patients with metastatic castration resistant prostate cancer received 177Lu PSMA I&T therapy. , 2020, Hellenic journal of nuclear medicine.

[41]  W. Wadsak,et al.  Prediction of response and survival after standardized treatment with 7400 MBq 177Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[42]  R. Hustinx,et al.  EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[43]  Amitabh Singh,et al.  Is 177Lu-PSMA an effective treatment modality for mCRPC patients with bone and visceral metastasis? , 2020, Hellenic journal of nuclear medicine.

[44]  M. Essler,et al.  Improving quality of life in patients with metastatic prostate cancer following one cycle of 177Lu-PSMA-617 radioligand therapy: a pilot study , 2020, Nuklearmedizin.

[45]  A. Celler,et al.  Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T , 2020, EJNMMI Physics.

[46]  O. Prante,et al.  Estimation of [177Lu]PSMA-617 tumor uptake based on voxel-wise 3D Monte Carlo tumor dosimetry in patients with metastasized castration resistant prostate cancer , 2020, Nuklearmedizin.

[47]  A. Haug,et al.  Dose Calculations and Dose-Effect Relationships in 177Lu-PSMA I&T Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer , 2020, Clinical nuclear medicine.

[48]  G. Glatting,et al.  Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry , 2020, EJNMMI Physics.

[49]  J. Czernin,et al.  Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study. , 2020, European urology.

[50]  M. L. Belli,et al.  Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[51]  R. Berger,et al.  A retrospective analysis of the safety and activity of Lutetium-177-PSMA radionuclide treatment in older patients with metastatic castration-resistant prostate cancer. , 2020, The oncologist.

[52]  R. Fimmers,et al.  Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial) , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[53]  M. Bartholomä,et al.  Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[54]  Kamaldeep,et al.  Examining Absorbed Doses of Indigenously Developed 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy. , 2020, Cancer biotherapy & radiopharmaceuticals.

[55]  T. Holland-Letz,et al.  Response Prediction of 177Lu-PSMA-617 Radioligand Therapy Using Prostate-Specific Antigen, Chromogranin A, and Lactate Dehydrogenase , 2020, The Journal of Nuclear Medicine.

[56]  R. Berger,et al.  Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer , 2020, Cancers.

[57]  Steffie M. B. Peters,et al.  Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study , 2020, Clinical Cancer Research.

[58]  T. Derlin,et al.  The Prostate , 2020 .

[59]  T. Derlin,et al.  Neuroendocrine Differentiation and Response to PSMA-Targeted Radioligand Therapy in Advanced Metastatic Castration-Resistant Prostate Cancer: A Single-Center Retrospective Study , 2020, The Journal of Nuclear Medicine.

[60]  K. Rahbar,et al.  Radioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[61]  M. Assadi,et al.  Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years , 2020, World journal of nuclear medicine.

[62]  R. Hicks,et al.  Radiation Dosimetry in 177Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors , 2019, The Journal of Nuclear Medicine.

[63]  W. Wadsak,et al.  Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[64]  W. Horninger,et al.  The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration–resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[65]  A. Seth,et al.  Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients. , 2019, Clinical nuclear medicine.

[66]  Ashutosh Kumar Singh,et al.  Safety Profile and Therapeutic Efficacy of One Cycle of Lu177-PSMA in End-Stage Metastatic Castration-Resistant Prostate Cancer Patients with Low Performance Status , 2019, Nuclear Medicine and Molecular Imaging.

[67]  D. Murphy,et al.  Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer , 2019, The Journal of Nuclear Medicine.

[68]  S. Basu,et al.  Therapeutic efficacy, Prognostic variables and Clinical Outcome of 177Lu-PSMA-617 PRLT in Progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason Score in such cohort. , 2019, The British journal of radiology.

[69]  W. Oyen,et al.  Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer , 2019, European urology.

[70]  N. Lenzo,et al.  Renal outcomes of radioligand therapy: experience of 177lutetium—prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer , 2019, Clinical kidney journal.

[71]  S. Ziegler,et al.  3D Monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3D localization of active bone marrow via Tc-99m-anti-granulocyte antibody SPECT/CT , 2019, EJNMMI Research.

[72]  R. McBean,et al.  Lu177‐PSMA therapy for men with advanced prostate cancer: Initial 18 months experience at a single Australian tertiary institution , 2019, Journal of medical imaging and radiation oncology.

[73]  B. Mofid,et al.  Efficacy and safety of 177Lutetium-prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer patients: First experience in West Asia – A prospective study , 2019, World Journal of Nuclear Medicine.

[74]  A. Aksu,et al.  The use of molecular volumetric parameters for the evaluation of Lu-177 PSMA I&T therapy response and survival , 2019, Annals of Nuclear Medicine.

[75]  M. Schwaiger,et al.  Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer. , 2019, European urology.

[76]  G. Krijger,et al.  First Experience With 177Lu-PSMA-617 Therapy for Advanced Prostate Cancer in the Netherlands , 2019, Clinical nuclear medicine.

[77]  Xiaoyuan Chen,et al.  Pretherapeutic 68Ga-PSMA-617 PET May Indicate the Dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in Main Organs and Tumor Lesions , 2019, Clinical nuclear medicine.

[78]  K. Rahbar,et al.  Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving 177Lu-PSMA-617 , 2019, Theranostics.

[79]  R. Epstein,et al.  Results of a Prospective Phase 2 Pilot Trial of 177Lu–PSMA‐617 Therapy for Metastatic Castration‐Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression , 2019, Clinical genitourinary cancer.

[80]  M. L. Belli,et al.  Dosimetry of 177Lu-PSMA-617 after Mannitol Infusion and Glutamate Tablet Administration: Preliminary Results of EUDRACT/RSO 2016-002732-32 IRST Protocol , 2019, Molecules.

[81]  G. Cheon,et al.  Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. , 2019, Endocrine-related cancer.

[82]  F. Mottaghy,et al.  68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[83]  B. Billah,et al.  Clinical Outcomes of 177Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy , 2019, The Journal of Nuclear Medicine.

[84]  G. Glatting,et al.  Modeling and Predicting Tumor Response in Radioligand Therapy , 2019, The Journal of Nuclear Medicine.

[85]  W. Wadsak,et al.  Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[86]  G. Feldmann,et al.  Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[87]  D. Murphy,et al.  Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes , 2018, The Journal of Nuclear Medicine.

[88]  R. Bundschuh,et al.  Role of textural heterogeneity parameters in patient selection for 177Lu-PSMA therapy via response prediction , 2018, Oncotarget.

[89]  N. Lenzo,et al.  Salvage Radiopeptide Therapy of Advanced Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen: Efficacy and Safety in Routine Practice. , 2018, Cancer biotherapy & radiopharmaceuticals.

[90]  U. Haberkorn,et al.  Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[91]  S. Ziegler,et al.  Patient-specific image-based bone marrow dosimetry in Lu-177-[DOTA0,Tyr3]-Octreotate and Lu-177-DKFZ-PSMA-617 therapy: investigation of a new hybrid image approach , 2018, EJNMMI Research.

[92]  R. Bundschuh,et al.  Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma , 2018, Clinical nuclear medicine.

[93]  M. Blaufox,et al.  SNMMI Procedure Standard/EANM Practice Guideline for Diuretic Renal Scintigraphy in Adults With Suspected Upper Urinary Tract Obstruction 1.0. , 2018, Seminars in nuclear medicine.

[94]  U. Haberkorn,et al.  Repeated 177Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq , 2018, The Journal of Nuclear Medicine.

[95]  K. Rahbar,et al.  Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[96]  F. Mottaghy,et al.  Relevant tumor sink effect in prostate cancer patients receiving 177Lu-PSMA-617 radioligand therapy , 2018, Nuklearmedizin.

[97]  R. Fimmers,et al.  Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy , 2017, Oncotarget.

[98]  K. Rahbar,et al.  177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[99]  E. Demirci,et al.  Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry , 2017, Molecular imaging and radionuclide therapy.

[100]  Rolf Fimmers,et al.  Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617 , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[101]  M. Schwaiger,et al.  Radiation Dosimetry for 177Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions , 2017, The Journal of Nuclear Medicine.

[102]  R. Fimmers,et al.  Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride. , 2017, Oncotarget.

[103]  R. Fimmers,et al.  Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617 , 2017, The Journal of Nuclear Medicine.

[104]  Clemens Decristoforo,et al.  The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[105]  W. Brenner,et al.  German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients , 2017, Journal of Nuclear Medicine.

[106]  Oliver Sartor,et al.  Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  G. Böning,et al.  Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer , 2016, Oncotarget.

[108]  U. Haberkorn,et al.  PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617 , 2016, The Journal of Nuclear Medicine.

[109]  K. Rahbar,et al.  Response and tolerability of a single dose of 177Lu-PSMA-DKFZ-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis , 2016 .

[110]  A. Drzezga,et al.  Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [177Lu]DKFZ-PSMA-617 , 2016, Molecular Imaging and Biology.

[111]  R. Baum,et al.  177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy , 2016, The Journal of Nuclear Medicine.

[112]  E. Demirci,et al.  Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[113]  K. Rahbar,et al.  Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study , 2015, EJNMMI Research.

[114]  Slave Trajanoski,et al.  Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis , 2009, Pathology & Oncology Research.

[115]  J. Bowie,et al.  A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. , 2003, Molecular biology of the cell.

[116]  D. Bostwick,et al.  Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. , 1998, Urology.

[117]  N. Bander,et al.  Constitutive and antibody-induced internalization of prostate-specific membrane antigen. , 1998, Cancer research.

[118]  T. Holland-Letz,et al.  Response Prediction of 177Lu-PSMA-617 Radioligand Therapy Using Prostate-Specific Antigen, Chromogranin A, and Lactate Dehydrogenase , 2019, The Journal of Nuclear Medicine.

[119]  B. Billah,et al.  Clinical Outcomes of 177Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy , 2019, The Journal of Nuclear Medicine.

[120]  M Essler,et al.  PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[121]  A. Seth,et al.  Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer , 2017, Nuclear medicine communications.

[122]  U. Haberkorn,et al.  Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[123]  P. Schellhammer,et al.  Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. , 1995, Urologic oncology.